FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Price, Forecast & Analysis
TSX:FRX • CA31447P1009
FRX.CA Key Statistics, Chart & Performance
The current stock price of FRX.CA is 10.495 CAD. In the past month the price decreased by -1.27%. In the past year, price increased by 22.18%.
FRX.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FRX.CA. When comparing the yearly performance of all stocks, FRX.CA turns out to be only a medium performer in the overall market: it outperformed 45.43% of all stocks.
FRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA. FRX.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FRX.CA Financial Highlights
Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by -475% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FRX.CA Forecast & Estimates
12 analysts have analysed FRX.CA and the average price target is 21.57 CAD. This implies a price increase of 105.5% is expected in the next year compared to the current price of 10.495.
For the next year, analysts expect an EPS growth of -248058267475566850% and a revenue growth -20.03% for FRX.CA
FRX.CA Ownership
FRX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 560.189M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 378.8M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 141.303M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 63.392M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 44.744M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| RVX | RESVERLOGIX CORP | N/A | 27.297M | ||
| HEM | HEMOSTEMIX INC | N/A | 15.079M | ||
| MPH | MEDICURE INC | N/A | 11.693M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.49M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About FRX.CA
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What does FENNEC PHARMACEUTICALS INC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
What is the stock price of FENNEC PHARMACEUTICALS INC today?
The current stock price of FRX.CA is 10.495 CAD. The price decreased by -0.33% in the last trading session.
Does FRX stock pay dividends?
FRX.CA does not pay a dividend.
How is the ChartMill rating for FENNEC PHARMACEUTICALS INC?
FRX.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for FRX.CA stock?
12 analysts have analysed FRX.CA and the average price target is 21.57 CAD. This implies a price increase of 105.5% is expected in the next year compared to the current price of 10.495.
What is FENNEC PHARMACEUTICALS INC worth?
FENNEC PHARMACEUTICALS INC (FRX.CA) has a market capitalization of 358.40M CAD. This makes FRX.CA a Small Cap stock.